On the Bid is a new Stockhead video series featuring a roundtable of experts discussing a new investment topic each week.

In this edition, host Oriel Morrison discusses mental health medical technology. The panel discuss the attributors impacting mental health globally such as COVID-19 and isolation, the changes in the medtech landscape, introduction of new technology to an ageing population and embracing new innovation.

On the panel this week is Brad O’Connor CEO of Cogstate (ASX:CGS) and Dr Evian Gordon, founder, chairman and CMO of Total Brain (ASX:TTB)

Cogstate is a leading neuroscience technology company optimising brain health assessments to advance the development of new medicines. Focused on brain health and the treatment of neurodegenerative diseases, such as Alzheimer’s disease.

Total Brain is a mental health and brain performance self-monitoring and self-care platform. The Total Brain app enables self-monitoring of the 12 brain capacities that define mental health, two mental states, and the risk of common mental health conditions.

The panel discuss a range of topics including the global impact of COVID-19  on mental health, embracing new technologies, introduction of new tech to ageing population, Total Brain and Cogstate’s company plans for 2023/24, what investors can expect in the coming months and more.  

So click above to tune in!

Read MoreMedtech

Featured Companies

You might be interested in